Answers are grounded in this paper and cite their sources.
This Viewpoint discusses the US Food and Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee’s recommendation to add 7 peptides to the compounding 503A Bulks List and the profound threat that compounding these peptides could represent to the drug-approval process and patients.
No takes yet. Share an insight, caveat, or question.
Samantaroy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: